European PRRSV strain

• US 8,765,142 B2
• Filed: 02/14/2012
• Issued: 07/01/2014
• Est. Priority Date: 02/17/2011
• Status: Active Grant

• Current Assignee: Boehringer Ingelheim Vetmedica GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim Vetmedica GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Kroll, Jeremy, Ohlinger, Volker, Orveillon, Francois-Xavier, Roof, Michael B., Utley, Philip, Vaughn, Eric Martin, Burgard, Kim, Layton, Sarah M., Pesch, Stefan, Piontkowski, Michael Dennis
• Primary Examiner(s): LI, BAO Q
• Application Number:
  US13/396,298
• Publication Number:
  US 20120213810A1
• Time in Patent Office: 868 Days
• US Class Current: 424/221.1
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/552 Veterinary vaccine
• CPC Class Codes: A61K 2039/575 humoral response
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C12N 2770/10021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2770/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2770/10064 by serial passage
• CPC Class Codes: C12N 2770/10071 Demonstrated in vivo effect
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.

Claims

1. An isolated live attenuated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) of a European type, which is of the strain deposited with European Collection of Cell Cultures (ECACC) under the Accession number ECACC 11012501 or Accession number ECACC 11012502.

2. The PRRSV of claim 1, wherein said virus is attenuated by passaging at least 36 times in cell culture such that when the modified virus is administered to a swine or other mammal prone to PRRSV, it fails to cause clinical signs of PRRSV disease but is capable of inducing an immune response that immunizes the mammal against pathogenic forms of PRRSV.

3. A method for the preparation of the live attenuated PRRSV according to claim 1, comprising adapting an MA 104-grown PRRSV of a European type to non-MA 104 mammalian cells.

11. A method for the preparation of a live attenuated vaccine for combating PRRS, comprising admixing a live attenuated PRRSV according to claim 1 with a pharmaceutically acceptable carrier.

12. The method according to claim 11, wherein the live attenuated PRRSV further comprises one or more additional European PRRSV strains selected from the group consisting of a PRRSV strain deposited under the Accession Numbers ECACC 04102703, ECACC 04102702, ECACC 04102704, CNCM Accession No. I-1140, CNCM Accession No I-1387, and CNCM Accession No I-1388.

13. The method according to claim 11, wherein the live attenuated PRRSV further comprises an adjuvant.

4. A vaccine for the protection of pigs against PRRSV infection, comprising (a) a live attenuated PRRSV deposited with European Collection of Cell Cultures (ECACC) under the Accession Number ECACC 11012502 or (b) a live attenuated PRRSV attenuated from a parental strain deposited at Accession Number ECACC 11012501, comprising adapting an MA 104-grown PRRSV of a European type to non-MA 104 mammalian cells, and a pharmaceutically acceptable carrier.

5. The vaccine according to claim 4, which further comprises one or more non-PRRSV attenuated or inactivated pathogens or antigenic material thereof.

6. The vaccine according to claim 5, wherein said non-PRRSV pathogens are selected from Pseudorabies virus, Porcine influenza virus, Porcine parvovirus, Transmissible gastroenteritis virus, Escherichia coli, Erysipelo rhusiopathiae, Bordetella bronchiseptica, Salmonella cholerasuis, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae.

7. The vaccine according to claim 4 which further comprises one or more additional European PRRSV strains selected from the group consisting of a PRRSV strain deposited under the Accession Numbers Lelystad virus strain (Lelystad Agent (CDI-NL-2.91), ECACC 04102703, ECACC 04102702, ECACC 04102704, CNCM Accession No. I-1140, CNCM Accession No I-1387, CNCM Accession No I-1388, ATCC VR 2332, VR 2385, VR 2386, VR 2429, VR 2474, and VR 2402;

CNCM I-1102, CNCM I-1140, CNCM I-1387, CNCM I-1388, ECACC V93070108, North American PRRS virus, pT7P129A;

ATCC deposit VR-2332, ATCC deposit VR-2368;

ATCC VR-2495;

ATCC VR 2385, ATCC VR 2386, ATCC VR 2429, ATCC VR 2474, and ATCC VR 2402.

8. The vaccine according to claim 4, which comprises a carrier that is suitable for intradermal or intramuscular application.

9. The vaccine according to claim 4, which is in freeze-dried form.

10. The vaccine of claim 4 wherein said vaccine comprises at least about 107 virus particles.